Physician profile
Ryan B Utarnachitt
NPI 1659545796
$1,434.13
in general payments reported to CMS, 2019-2025
22 companies · $643 in 2025
The $643 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.02 · 2021: $116 · 2022: $88.20 · 2023: $266 · 2024: $243 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.28 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $305.11 | 2023-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $268.25 | 2019-2025 | Rinvoq, Skyrizi |
| Medtronic, INC. | $116.47 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.21 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $94.49 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $92.94 | 2022-2025 | Dupixent |
| Enterra Medical, INC. | $89.95 | 2025 | |
| Pfizer INC. | $48.86 | 2019-2025 | |
| Ardelyx, INC. | $48.12 | 2023-2025 | Ibsrela |
| Ucb, INC. | $34.26 | 2024 | Cimzia |
| Alnylam Pharmaceuticals INC. | $31.96 | 2025 | Givlaari |
| Lilly USA, LLC | $28.41 | 2024 | Omvoh |
| Sandoz INC. | $23.48 | 2024 | Hyrimoz |
| Nestle Healthcare Nutrition INC. | $23.28 | 2023 | |
| Gilead Sciences, INC. | $21.14 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micro-Tech Endoscopy USA, INC. | $20.54 | 2024 | Biopsy Forceps |
| Celgene Corporation | $20.12 | 2024 | Zeposia |
| Braintree Laboratories, INC. | $18.97 | 2025 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $14.67 | 2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $13.94 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $10.96 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,623.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Utarnachitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.